Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20Thoracic 1Other solid neoplasm 1NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Melanoma 1103Carcinoma, Non-Small-Cell Lung 281Neoplasms 199Keratosis, Actinic 181Carcinoma, Renal Cell 162Skin Neoplasms 143Colorectal Neoplasms 142Neoplasm Metastasis 140Squamous Cell Carcinoma of Head and Neck 134Breast Neoplasms 118Ovarian Neoplasms 114Carcinoma, Basal Cell 97Stomach Neoplasms 94Pancreatic Neoplasms 93Lung Neoplasms 91Head and Neck Neoplasms 90Lymphoma, T-Cell, Cutaneous 88Uterine Cervical Neoplasms 75Triple Negative Breast Neoplasms 74Sarcoma 68Carcinoma, Hepatocellular 67Prostatic Neoplasms 65Uveal Melanoma 64Carcinoma, Merkel Cell 64Urinary Bladder Neoplasms 63Esophageal Neoplasms 61Carcinoma, Transitional Cell 57Lymphoma 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenoma × Dermatologic × Clear all
NCT06398418 2025-09-04

R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors

Rise Therapeutics LLC

Phase 1 Recruiting
33 enrolled
Dermatologic

Adenoma, Melanoma, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡